Antibody–Drug Conjugates for Solid Tumors: Progress, Possibilities, and Implications for Care
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024. Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Chair/Planner Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc. Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited. Faculty/Planner Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna. Speakers Bureau participant with Horizon CME and OncLive. Faculty/Planner Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of: Speakers Bureau participant with Incyte. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Deep Insight Into Immuno-Oncology: Immunotherapy Pathways, Targets, and Biomarkers

Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology Conference

Targeting With Precision in Advanced Ovarian Cancer

SABCS 2024: People's choice - future directions in antibody drug conjugates

Rocky Mountain IBD- March 14- Saturday Morning Recording

ISHLT Recap Webinar

Antibody-drug Conjugates in the Clinic:

Int'l Neuroblastoma Webinar Series Session #18: BCC Clinical Trials Update with Dr. Giselle Sholler

The Latest Treatments for Uterine Cancer and What’s in the Pipeline

Expanding the Benefits of Immuno-Oncology Through Novel Rational Targets and Combinations

LRR Microbiology for FMGE 2026 By Dr. Preeti Sharma

Hepatology and Liver Transplantation Webinar | MASLD Highlights 2026

The Latest in Gynecologic Cancers: The ABCs of ADCs (antibody-drug conjugates)

Modern Interventions in Neuroendocrine Carcinoma: DLL3-Directed BiTE Therapy in Community Settings

Drs. Kopetz, Eng & Fakih discuss #CRC updates at #ASCO26: bit.ly/2026CRC-Y

Immuno-Oncology: A Future Look

Riding the ADC Wave Into Gynecologic Cancer Care

Curing metastatic solid tumours with immune checkpoint inhibitors by Professor James Larkin

Baim Grand Rounds Katherine Tuttle 15Jun2026

